Ramaswamy Govindan

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. pmc Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Vamsidhar Velcheti
    Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA
    Biologics 4:83-90. 2010
  2. doi request reprint A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Ramaswamy Govindan
    Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    J Thorac Oncol 4:220-6. 2009
  3. doi request reprint Summary of presentation from the targeted therapy in lung cancer meeting
    Ramaswamy Govindan
    Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 6:S1757. 2011
  4. doi request reprint Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer
    Ramaswamy Govindan
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 6:790-5. 2011
  5. pmc Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407
    Ramaswamy Govindan
    Washington University School of Medicine, 4960 Children s Place, St Louis, MO 63110, USA
    J Clin Oncol 29:3120-5. 2011
  6. pmc Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University School of Medicine, Alvin J Siteman Comprehensive Cancer Center, 4921 Parkview Place, St Louis, MO, USA
    J Clin Oncol 28:2475-80. 2010
  7. doi request reprint Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis
    Janakiraman Subramanian
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 5:23-8. 2010
  8. ncbi request reprint A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report
    Giancarlo A Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 1:972-8. 2006
  9. ncbi request reprint Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer
    Vamsidhar Velcheti
    Division of Oncology, Alvin J Siteman Cancer Center Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 2:875-6. 2007
  10. doi request reprint A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer
    Boone Goodgame
    Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Oncol 31:22-8. 2008

Collaborators

Detail Information

Publications86

  1. pmc Management of patients with advanced non-small cell lung cancer: role of gefitinib
    Vamsidhar Velcheti
    Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA
    Biologics 4:83-90. 2010
    ..This review will discuss the results of these large randomized studies and discuss the role of gefitinib in the treatment of advanced NSCLC...
  2. doi request reprint A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104
    Ramaswamy Govindan
    Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63110, USA
    J Thorac Oncol 4:220-6. 2009
    ..To assess the efficacy and toxicity of carboplatin, etoposide, and exisulind as initial therapy for extensive stage small cell lung cancer...
  3. doi request reprint Summary of presentation from the targeted therapy in lung cancer meeting
    Ramaswamy Govindan
    Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 6:S1757. 2011
    ..The articles in this supplement should be viewed more as meeting reports than as exhaustive and comprehensive review articles...
  4. doi request reprint Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer
    Ramaswamy Govindan
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 6:790-5. 2011
    ..We conducted a multicenter phase II study in previously treated patients with NSCLC to evaluate the efficacy of single-agent S-1 in a predominantly non-Asian population...
  5. pmc Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407
    Ramaswamy Govindan
    Washington University School of Medicine, 4960 Children s Place, St Louis, MO 63110, USA
    J Clin Oncol 29:3120-5. 2011
    ..Cancer and Leukemia Group B conducted a randomized phase II trial to investigate two novel chemotherapy regimens in combination with concurrent thoracic radiation therapy (TRT)...
  6. pmc Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117
    Jeffrey D Bradley
    Department of Radiation Oncology, Washington University School of Medicine, Alvin J Siteman Comprehensive Cancer Center, 4921 Parkview Place, St Louis, MO, USA
    J Clin Oncol 28:2475-80. 2010
    ..The radiation dose was 74 Gy given in 37 fractions. Radiation therapy volumes included those of the gross tumor and involved nodes. The volume of lung at or exceeding 20 Gy (V20) was mandated to be <or= 30%...
  7. doi request reprint Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis
    Janakiraman Subramanian
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 5:23-8. 2010
    ....
  8. ncbi request reprint A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report
    Giancarlo A Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 1:972-8. 2006
    ..In addition, we studied the correlation between certain genotypes of enzymes involved in irinotecan metabolism with efficacy and toxicity...
  9. ncbi request reprint Radiation-induced myonecrosis presenting as a subcutaneous mass after combined modality therapy for non-small cell lung cancer
    Vamsidhar Velcheti
    Division of Oncology, Alvin J Siteman Cancer Center Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 2:875-6. 2007
  10. doi request reprint A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer
    Boone Goodgame
    Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Am J Clin Oncol 31:22-8. 2008
    ..There are no reliable markers to predict recurrence in resected Stage I non-small cell lung cancer (NSCLC). A validated clinical model to estimate the risk of recurrence would help select patients for adjuvant therapy...
  11. doi request reprint Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey
    Daniel Morgensztern
    Division of Hematology Oncology, St Louis Veterans Hospital, St Louis, Missouri, USA
    J Thorac Oncol 5:29-33. 2010
    ..We examined the recent changes in stage distribution in newly diagnosed patients with non-small cell lung cancer (NSCLC) using a national database to assess the impact of recent advances in imaging modalities...
  12. doi request reprint Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005
    Daniel Morgensztern
    Division of Hematology Oncology, St Louis Veterans Hospital, St Louis, Missouri, USA
    J Thorac Oncol 4:1524-9. 2009
    ..Therefore, we conducted a study to evaluate for survival changes in a large national cancer registry database...
  13. doi request reprint Risk of recurrence of resected stage I non-small cell lung cancer in elderly patients as compared with younger patients
    Boone Goodgame
    Division of Medical Oncology, The Alvin J Siteman Cancer Center, St Louis, Missouri, USA
    J Thorac Oncol 4:1370-4. 2009
    ..We report the outcomes in elderly patients (70 years or older) with stage I NSCLC after surgical resection...
  14. doi request reprint Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003
    Daniel Morgensztern
    Department of Medicine, Division of Medical Oncology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
    J Thorac Oncol 7:1479-84. 2012
    ..We conducted a Surveillance, Epidemiology, and End Results (SEER) database analysis to evaluate the prognostic significance of tumor size in patients with unresected stage III NSCLC...
  15. doi request reprint Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial
    Ezra E W Cohen
    Section of Hematology and Oncology, Department of Medicine, and Comprehensive Cancer Center, University of Chicago, Chicago, IL, USA
    Clin Lung Cancer 13:123-8. 2012
    ..This trial focused on optimally combining existing targeted therapies and cytotoxic chemotherapy in the treatment of unselected patients with advanced non-small-cell lung cancer (NSCLC)...
  16. pmc A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117
    Jeffrey D Bradley
    Washington University School of Medicine, St Louis, Missouri, USA
    Int J Radiat Oncol Biol Phys 77:367-72. 2010
    ....
  17. doi request reprint A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors
    Daniel Morgensztern
    Department of Medicine, Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Chemotherapy 55:441-5. 2009
    ..Preclinical studies have shown synergism between topoisomerase I and II inhibitors...
  18. doi request reprint Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer
    Daniel Morgensztern
    Department of Medicine, Division of Medical Oncology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, USA
    J Thorac Oncol 7:1485-9. 2012
    ..We evaluated the clinical characteristics associated with MPE at presentation and the prognostic impact of MPE at presentation in patients with stage M1b NSCLC...
  19. doi request reprint Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Cancer Chemother Pharmacol 63:451-8. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics of weekly docosahexaenoic acid-paclitaxel (DHA-paclitaxel), a taxane fatty acid conjugate...
  20. doi request reprint The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Daniel Morgensztern
    Division of Oncology, Department of Medicine, Washington University School of Medicine, USA
    J Thorac Oncol 3:135-9. 2008
    ..To study the impact of F-fluorodeoxyglucose positron emission tomography (FDG-PET) on stage distribution and survival for patients with newly diagnosed non-small cell lung cancer (NSCLC)...
  21. ncbi request reprint Presentation and stage-specific outcomes of lifelong never-smokers with non-small cell lung cancer (NSCLC)
    Janakiraman Subramanian
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 2:827-30. 2007
    ..Approximately 10% of patients with lung cancer are life long never-smokers. There are only limited data available on the clinical characteristics and outcomes of lung cancer in never-smokers from the Western hemisphere...
  22. ncbi request reprint Smoking relapse during the first year after treatment for early-stage non-small-cell lung cancer
    Mark S Walker
    Department of Medicie, Washingon University School of Medicine, St Louis, Missouri, USA
    Cancer Epidemiol Biomarkers Prev 15:2370-7. 2006
    ..Despite this, many continue to smoke, with estimates ranging from 13% to approximately 60%...
  23. ncbi request reprint Recent advances and future perspectives in the management of lung cancer
    Alexander Sasha Krupnick
    Washington University School of Medicine, St Louis, MO, USA
    Curr Probl Surg 42:540-610. 2005
  24. ncbi request reprint A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer
    Ramaswamy Govindan
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Oncol Rep 15:123-7. 2006
    ..The median time to progression was 5.86 months (95% CI 2.50-9.22), and median survival was 10.96 months (95% CI 1.42-20.51) with a 1-year survival rate of 50%. This combination may be important for patients with NSCLC...
  25. ncbi request reprint Positron emission tomography in limited-stage small-cell lung cancer: a prospective study
    Jeffrey D Bradley
    Department of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4921 Parkview Place, St Louis, MO 63110, USA
    J Clin Oncol 22:3248-54. 2004
    ....
  26. doi request reprint A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer
    Saiama N Waqar
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Chemotherapy 59:8-13. 2013
    ..Resistance to tyrosine kinase inhibitor therapy is mediated by the mammalian target of rapamycin (mTOR) pathway, and may be reversed by using mTOR inhibitors...
  27. doi request reprint Recent advances in lung cancer: summary of presentations from the 47 th annual meeting of the American Society of Clinical Oncology (ASCO) 2011
    Janakiraman Subramanian
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thorac Oncol 7:260-5. 2012
    ..For this review, we have selected presentations that primarily have an impact on clinical practice, and some presentations regarding emerging therapeutic agents...
  28. ncbi request reprint A Phase I trial of weekly docetaxel and topotecan for solid tumors
    Wan Teck Lim
    Alvin J Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Acta Oncol 47:311-5. 2008
    ..This study defines the maximum tolerated dose (MTD) and dose-limiting toxicity of weekly topotecan when administered in combination with docetaxel 25 mg/m(2) given day 1, 8,15 every 28 days...
  29. ncbi request reprint Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience
    Aruna Kommareddy
    Division of Medical Oncology, Alvin J Siteman Cancer Center, Washington University School of Medicine, 4960 Children s Place, P O Box 8056, St Louis, MO 63110, USA
    Lung Cancer 45:221-5. 2004
    ..1 and 2.9 months, respectively. Toxicities were minimal and included rash and diarrhea. Gefitinib was well tolerated and had interesting activity in previously untreated patients with advanced NSCLC...
  30. ncbi request reprint Is there a role for cetuximab in non small cell lung cancer?
    Daniel Morgensztern
    Department of Medicine, St Louis Veterans Affairs Medical Center, St Louis, Missouri, USA
    Clin Cancer Res 13:s4602-5. 2007
    ..Research is also ongoing to define the role of cetuximab in combination with other targeted agents. This review will summarize the results of recently published studies on cetuximab and outline current research with this agent in NSCLC...
  31. doi request reprint Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials
    Maria Q Baggstrom
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 6:98-102. 2011
    ..Only a small fraction of patients with lung cancer are enrolled in clinical trials. It is critical to understand the barriers to participation in lung cancer clinical trials...
  32. ncbi request reprint Lung cancer in never smokers: a review
    Janakiraman Subramanian
    Department of Medicine and Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    J Clin Oncol 25:561-70. 2007
    ..This review will summarize available data on the epidemiology, risk factors, molecular genetics, management options, and outcomes of LCINS...
  33. ncbi request reprint A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
    Paula M Fracasso
    The Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 13:986-93. 2007
    ..This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects of cetuximab on patients with epithelial malignancies...
  34. doi request reprint A phase I study of docetaxel and bexarotene
    Jonathan D Wildi
    Department of Medicine, Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA
    Chemotherapy 54:125-30. 2008
    ..We conducted a single-arm, dose-escalation, phase 1 clinical trial in order to define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of bexarotene in combination with docetaxel...
  35. ncbi request reprint Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, 4960 Children s Place, Suite 108, St Louis, MO 63110, USA
    Clin Cancer Res 11:2300-4. 2005
    ..The Cancer and Leukemia Group B conducted a phase II study of gefitinib, an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, in patients with previously untreated malignant mesothelioma...
  36. ncbi request reprint Clinical applications of The Cancer Genome Atlas project (TCGA) for squamous cell lung carcinoma
    Siddhartha Devarakonda
    Department of Internal Medicine, St Luke s Hospital, Chesterfield, Missouri, USA
    Oncology (Williston Park) 27:899-906. 2013
    ..We summarize here key findings from the comprehensive analysis of squamous cell lung cancer by The Cancer Genome Atlas group and discuss the clinical implications of these findings...
  37. ncbi request reprint Smoking urges and relapse among lung cancer patients: findings from a preliminary retrospective study
    Mark S Walker
    Department of Medicine, Washington University School of Medicine, St Louis, MO 63130, USA
    Prev Med 39:449-57. 2004
    ..As part of a prospective study of relapse to smoking among previously resected lung cancer patients, we conducted a retrospective survey to examine factors that may contribute to relapse...
  38. ncbi request reprint Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
    Ramaswamy Govindan
    Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 24:4539-44. 2006
    ..Small-cell lung cancer (SCLC) is a histologic subtype of lung cancer with a distinct biology and clinical course. It has been observed that the incidence of SCLC has been decreasing over the last several years...
  39. ncbi request reprint Review of ongoing clinical trials in non-small cell lung cancer: a status report for 2009 from the ClinicalTrials.gov website
    Janakiraman Subramanian
    Division of Oncology, Department of Medicine, Washington University School of Medicine, 660 S Euclid, Box 8056, St Louis, MO 63110, USA
    J Thorac Oncol 5:1116-9. 2010
    ..A survey of ongoing clinical trials in NSCLC in the ClinicalTrials.gov website would help identify areas that require further attention in the future...
  40. ncbi request reprint Prognostic value of fluorodeoxyglucose positron emission tomography in non-small cell lung cancer: a review
    Giancarlo Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 1:152-9. 2006
    ..In this review, we critically examine the published studies on the utility of FDG-PET as a prognostic tool in patients with NSCLC and provide direction for future research...
  41. ncbi request reprint Differential prognostic impact of comorbidity
    William L Read
    Department of Otolaryngology Head and Neck Surgery, Washington University School of Medicine, 660 S Euclid Ave, Campus Box 8115, St Louis, MO 63110, USA
    J Clin Oncol 22:3099-103. 2004
    ..We hypothesized that the prognostic impact of comorbidities would be greatest for patients with cancers associated with a long natural history and least in patients with aggressive cancers...
  42. doi request reprint Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer
    Rajesh N Keswani
    Division of Gastroenterology, Washington University School of Medicine, St Louis, Missouri, USA
    Gastrointest Endosc 69:1210-7. 2009
    ..Although EUS-guided FNA (EUS-FNA) and 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) are both used in the staging of esophageal cancer, the utility of routinely performing both tests is unclear...
  43. doi request reprint EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
    Thomas Fong
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Thorac Oncol 3:303-10. 2008
    ..This review will summarize the results of clinical trials on erlotinib or gefitinib in the first-line treatment of select and unselected patients with NSCLC and describe ongoing studies with these agents in NSCLC...
  44. ncbi request reprint A phase I study of temsirolimus and thoracic radiation in non-small-cell lung cancer
    Saiama N Waqar
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO
    Clin Lung Cancer 15:119-23. 2014
    ..Inhibition of the mTOR pathway has been found to augment the cytotoxic effect of radiation in preclinical studies. There is scant clinical experience with mTOR inhibitors and radiation...
  45. ncbi request reprint Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B
    Gerald Clamon
    Department of Internal Medicine, University of Iowa, Iowa City, Iowa 52242 1099, USA
    Cancer 103:1670-5. 2005
    ..The objective of this Phase II study was to determine whether trastuzumab would effect responses in patients with nonsmall cell lung carcinoma who had tumors that overexpressed HER-2...
  46. ncbi request reprint Metastatic cancer involving bladder: a review
    Vamsidhar Velcheti
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Can J Urol 14:3443-8. 2007
    ..Bladder is not a common site for metastasis of cancer and often goes undiagnosed in the clinical follow up of cancer patients. We reviewed the literature for published reports on metastatic cancer involving bladder...
  47. pmc A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
    Yan Lu
    Department of Surgery, Washington University School of Medicine, St Louis, Missouri, United States of America
    PLoS Med 3:e467. 2006
    ..As a consequence, it is not possible to select those high-risk patients for more aggressive therapies and assign less aggressive treatments to patients at low risk for recurrence...
  48. ncbi request reprint Pneumocystis pneumonia in a patient with non-small cell lung cancer (NSCLC) treated with pemetrexed containing regimen
    Vamsidhar Velcheti
    Department of Medicine, Washington University School of Medicine, St Louis, MO, United States
    Lung Cancer 57:240-2. 2007
    ..To our knowledge, this is the first report on pneumocystis pneumonia following administration of pemetrexed containing regimen...
  49. ncbi request reprint The role of docetaxel in N2 locally advanced non-small-cell lung cancer
    Giancarlo Pillot
    Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Lung Cancer 7:S87-92. 2005
    ..In addition, we discuss the role of docetaxel induction therapy before surgery or definitive radiation therapy. Additionally, we address the role of docetaxel in consolidation therapy in patients with locally advanced NSCLC...
  50. ncbi request reprint Chemotherapy for metastatic NSCLC: current status and future direction
    Ramaswamy Govindan
    Department of Medicine, Washington University, St Louis, MO, USA
    Nat Clin Pract Oncol 2:238-9. 2005
  51. doi request reprint Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Janakiraman Subramanian
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Clin Lung Cancer 11:311-9. 2010
    ..This review summarizes the currently available data on VEGFR TKIs in the treatment of NSCLC...
  52. ncbi request reprint Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    Oncology (Williston Park) 17:27-31. 2003
    ..However, this combination chemotherapy regimen has an unacceptable rate of febrile neutropenia. This regimen needs to be modified to reduce the incidence of febrile neutropenia...
  53. doi request reprint Molecularly targeted therapies in locally advanced non-small-cell lung cancer
    Siddhartha Devarakonda
    Department of Internal Medicine, St Luke s Hospital, Chesterfield, MO, USA
    Clin Lung Cancer 14:467-72. 2013
    ..We review the results of these trials and present the outline of a proposed prospective clinical trial to evaluate targeted drugs in molecularly selected group of patients with locally advanced NSCLC. ..
  54. doi request reprint A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer
    Ramaswamy Govindan
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA
    Clin Lung Cancer 11:8-12. 2010
    ..Irreversible inhibitors of EGFR and HER2 are novel agents in clinical development that might have the potential to prevent and overcome acquired resistance to first-generation EGFR inhibitors...
  55. pmc Genomic landscape of non-small cell lung cancer in smokers and never-smokers
    Ramaswamy Govindan
    Department of Internal Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Cell 150:1121-34. 2012
    ..Cell-cycle and JAK-STAT pathways are significantly altered in lung cancer, along with perturbations in 54 genes that are potentially targetable with currently available drugs...
  56. doi request reprint Locally advanced non-small cell lung cancer: the past, present, and future
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 3:917-28. 2008
    ..This review will discuss these issues in detail and outline the strategies that need to be employed to improve the outcomes in patients with locally advanced NSCLC...
  57. ncbi request reprint Adjuvant chemotherapy for lung cancer: cisplatin doublets only?
    Daniel Morgensztern
    Division of Oncology, Department of Medicine, Washington University School of Medicine, and Division of Hematology and Oncology, St Louis Veterans Affairs Medical Center, St Louis, Missouri
    J Natl Compr Canc Netw 6:277-84. 2008
    ..Furthermore, molecular predictors of resistance may guide the selection of chemotherapy in this setting...
  58. ncbi request reprint Response to bortezomib (velcade) in a case of advanced bronchiolo-alveolar carcinoma (BAC). A case report
    Janakiraman Subramanian
    Department of Medicine, St Luke s Hospital, Chesterfield, MO, USA
    Lung Cancer 51:257-9. 2006
    ..Based on observations like this and those seen in phase I studies with bortezomib, this agent is being studied now in patients with bronchio-alevolar cancer...
  59. ncbi request reprint Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474
    Daniel Morgensztern
    Alvin J Siteman Cancer Center at Washington University School of Medicine, Division of Oncology, 4960 Children s Place, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 6:545-51. 2006
    ..Several small molecule antiangiogenic agents are in development. In this article, currently available data from clinical trials of antiangiogenic compounds in advanced non-small cell lung cancer are reviewed...
  60. ncbi request reprint Irinotecan and carboplatin in metastatic or recurrent non-small-cell lung cancer
    Ramaswamy Govindan
    Department of Medicine, Washington University, School of Medicine, St Louis, Missouri, USA
    Oncology (Williston Park) 17:27-9. 2003
    ..The regimen of irinotecan and carboplatin administered once every 3 weeks demonstrates early evidence of activity, and is tolerable and convenient. The main toxicity is hematologic. This study is ongoing and actively accruing patients...
  61. doi request reprint Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer
    Daniel Morgensztern
    Division of Medical Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Clin Lung Cancer 12:94-9. 2011
    ..We report on selected studies from the developmental therapeutics track (abstracts 2500-2613 and 3000-3108) that may be of interest to the thoracic oncology community...
  62. doi request reprint Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic
    Andrea Wang-Gillam
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 28:3803-7. 2010
    ..Activation of clinical trials is a lengthy process. We studied the procedures and time required to activate lung cancer clinical trials in a US academic center compared with a European center...
  63. doi request reprint Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site
    Janakiraman Subramanian
    Department of Medicine, University of Tennessee Medical Center, Knoxville, Tennessee, USA
    J Thorac Oncol 8:860-5. 2013
    ..gov registry in 2012, and we also compared this data to a similar survey conducted by us in 2009...
  64. ncbi request reprint The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database
    William L Read
    Division of Oncology, Washington University School of Medicine, Campus Box 8056, 660 South Euclid Ave, St Louis, MO 63110, USA
    Lung Cancer 45:137-42. 2004
    ..The 1 year survival rate is significantly better for BAC patients relative to other histological subtypes of NSCLC. There has not been a marked increase in the incidence of BAC reported to SEER over the past 20 years...
  65. doi request reprint Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology
    Daniel Morgensztern
    Division of Oncology, Washington University School of Medicine and Alvin J Siteman Cancer Center, St Louis, MO 63021, USA
    Clin Lung Cancer 9:S57-61. 2008
    ....
  66. ncbi request reprint Second-line therapy for esophageal cancer
    Mike G Martin
    Hematology Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Expert Rev Anticancer Ther 7:871-6. 2007
    ..This review summarizes the recent advances in second-line therapy for esophageal cancer...
  67. ncbi request reprint Cetuximab in advanced non-small cell lung cancer
    Ramaswamy Govindan
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    Clin Cancer Res 10:4241s-4244s. 2004
    ..Molecular mechanisms predicting response to cetuximab therapy are currently not well understood. Studies are ongoing to assess the single-agent activity of cetuximab in metastatic NSCLC...
  68. doi request reprint Summary of presentations from the 46th annual meeting of the American Society of Clinical Oncology (2010): focus on supportive care issues related to lung cancer
    Leigh Boehmer
    Department of Pharmacy, Barnes Jewish Hospital, St Louis, Missouri, USA
    J Thorac Oncol 6:645-9. 2011
    ..Supportive care measures help ensure optimal quality of life during difficult psychologic and social situations. Research in the area of supportive care in patients with cancer should be made a priority...
  69. doi request reprint Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) focus on tumor biology and biomarkers related to lung cancer
    Janakiraman Subramanian
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 6:399-403. 2011
    ....
  70. ncbi request reprint Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results
    Ramaswamy Govindan
    Alvin J Siteman Cancer Center at Washington University School of Medicine St Louis, Missouri 63110, USA
    Oncology (Williston Park) 18:18-21. 2004
    ..The pCR rate of 22% in this study is similar to that reported with the use of preoperative chemoradiation in other trials. Further follow-up is necessary to assess the impact of maintenance therapy with celecoxib on overall survival...
  71. ncbi request reprint Lung cancer in 'Never-smokers': a unique entity
    Janakiraman Subramanian
    Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Oncology (Williston Park) 24:29-35. 2010
    ..In this review, we summarize the existing body of knowledge on lung cancer in never-smokers...
  72. ncbi request reprint Best of the month: a roundup of articles published in recent months
    Daniel Morgensztern
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thorac Oncol 5:1305-7. 2010
    ....
  73. doi request reprint A survey of Internet utilization among patients with cancer
    Kimra Castleton
    Alvin J Siteman Cancer Center at Washington University School of Medicine in St Louis, St Louis, MO 63100, USA
    Support Care Cancer 19:1183-90. 2011
    ....
  74. doi request reprint Molecular genetics of lung cancer in people who have never smoked
    Janakiraman Subramanian
    Department of Medicine, Washington University School of Medicine, St Louis, MO, USA
    Lancet Oncol 9:676-82. 2008
    ..Here, we review published studies of the molecular genetics of lung cancer in never smokers and identify the specific differences from tobacco-associated lung cancer...
  75. doi request reprint Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009)
    Boone Goodgame
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 4:1293-300. 2009
    ....
  76. ncbi request reprint Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
    Ramaswamy Govindan
    Washington University School of Medicine, Department of Medical Oncology, 660 S Euclid Ave Box 8056, St Louis, MO 63110, USA
    Lung Cancer 53:331-7. 2006
    ..3%). Complete and partial response rates were 0.7 and 5.6%, respectively, and 40.6% had stable disease. Median survival was 6 months, and estimated 1-year survival was 29.7%. The majority of patients did not receive subsequent CT...
  77. ncbi request reprint In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM
    Farrokh Dehdashti
    Division of Nuclear Medicine, Edward Mallinckrodt Institute of Radiology, St Louis, MO 63110, USA
    Eur J Nucl Med Mol Imaging 30:844-50. 2003
    ..04; P=0.9). (60)Cu-ATSM-PET can be readily performed in patients with NSCLC and the tumor uptake of (60)Cu-ATSM reveals clinically unique information about tumor oxygenation that is predictive of tumor response to therapy...
  78. ncbi request reprint Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
    Paula M Fracasso
    Alvin J Siteman Cancer Center, St Louis, Missouri 63110, USA
    Cancer 98:610-7. 2003
    ..The authors conducted a Phase I trial to evaluate the maximum tolerated dose (MTD), toxicities, and effect of dose sequencing of this combination in patients with advanced malignancies...
  79. ncbi request reprint Management of patients with non-small cell lung cancer and poor performance status
    Ramaswamy Govindan
    Department of Medicine, Washington University School of Medicine, Suite 108, 4960 Children s Place, St Louis, MO 63110, USA
    Curr Treat Options Oncol 4:55-9. 2003
    ..The suggested treatment options for patients with metastatic disease and poor PS are single-agent chemotherapy or supportive care...
  80. pmc A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer
    Maria Q Baggstrom
    Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, Missouri, USA
    J Thorac Oncol 6:1757-60. 2011
    ..We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC)...
  81. ncbi request reprint Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation
    Matthew Arquette
    Washington University, St Louis, MO 63110, USA
    Semin Radiat Oncol 12:59-61. 2002
    ..These results differ from the use of amifostine in non-small cell lung cancer in which there is the observation of esophageal protection...
  82. ncbi request reprint Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies
    Ramaswamy Govindan
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 24:4848-54. 2006
    ..To evaluate the effect of bexarotene on survival in patients with relapsed non-small-cell lung cancer (NSCLC)...
  83. ncbi request reprint Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status
    Ramaswamy Govindan
    Washington University School of Medicine, St Louis, MO, USA
    Semin Oncol 31:27-31. 2004
    ..It is hoped that their findings will aid in determining the best treatment options for these patients...
  84. pmc EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity
    Haris Vikis
    Washington University, St Louis, Missouri, USA
    Cancer Res 67:4665-70. 2007
    ..Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer...
  85. ncbi request reprint Hedgehog signaling pathway and lung cancer
    Vamsidhar Velcheti
    Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    J Thorac Oncol 2:7-10. 2007
    ..We review the biology of the hedgehog signaling pathway and its potential role in the development of lung cancer...
  86. pmc Identification of a novel tumor suppressor gene p34 on human chromosome 6q25.1
    Min Wang
    School of Medicine, Washington University, 660 Euclid Avenue, St Louis, MO, USA
    Cancer Res 67:93-9. 2007
    ..Our results suggest that p34 may be a novel tumor suppressor gene involved in sporadic lung cancer but it seems not to be the candidate familial lung cancer susceptibility gene linked to chromosomal region 6q23-25...